Contact information
Research groups
Collaborators
-
Lars Fugger
Professor of Neuroimmunology
-
Gabriele DeLuca
Professor of Clinical Neurology and Experimental Neuropathology
-
Jacqueline Palace
Consultant Neurologist and Professor of Clinical Neurology
-
Kevin Talbot
Head of Department and Professor of Motor Neuron Biology
-
Ruth Geraldes
Consultant Neurologist
Kate Attfield
PhD
Doctor of Immunology
- Principal Investigator
- D.Phil Supervisor
- Oxford University Hospitals Trust NHS Tissue Bank Co-ordinator
Dr Kate Attfield is an immunologist, with a strong interest in understanding how the immune system is shaped by genetics, epigenetics and the environment. After completing her PhD in 2009 at the University of Southampton, Kate then joined Professor Lars Fugger's group at the University of Oxford, where she has spent the last 17 years building a highly collaborative and multi-disciplinary research team.
With a key focus in neuroinflammatory diseases, such as multiple sclerosis, Kate co-leads a team of scientists who work closely with the clinical team at the John Radcliffe hospital to perform pioneering and cutting edge research using samples donated by patients living with MS as well as other neuroinflammatory conditions, such as neuromyelitis optica spectrum disorder (NMOSD).
With expertise in single cell multiomics, spatial transcriptomics and in vitro perturbation and functional models, our research team aims to expose the discrete and transitioning immune cell states that drive disease processes and to target and develop new therapeutics for patients that allow enhanced specificity, safety and longer term efficacy than current treatment options.
Recent publications
Identification of genetic risk loci associated with aquaporin 4-positive neuromyelitis optica spectrum disorder: a genome-wide association study
Journal article
Attfield KE. et al, (2026), The Lancet Neurology, 25, 482 - 491
A HIF1A variant impacts long-term disability and smoldering inflammation in multiple sclerosis.
Journal article
Giordano A. et al, (2026), Acta Neuropathol, 151
T cells turn in Alzheimer’s disease
Journal article
Skelly D. et al, (2025), Brain, 148, 3034 - 3036
A repair pathway lost in multiple sclerosis provides a new drug opportunity.
Journal article
Jensen LT. et al, (2024), Nat Immunol, 25, 385 - 386
Antibody agonists trigger immune receptor signaling through local exclusion of receptor-type protein tyrosine phosphatases
Journal article
Lippert AH. et al, (2024), Immunity, 57, 256 - 270.e10
Elevated genetic risk for multiple sclerosis emerged in steppe pastoralist populations.
Journal article
Barrie W. et al, (2024), Nature, 625, 321 - 328